Liposomes, New Carriers for Delivery of Genes and Anticancer Drugs: A Systematic Review Publisher Pubmed



Salari N¹ ; Rasoulpoor S² ; Valipour E³ ; Mansouri K² ; Bartina Y⁴ ; Dokaneheifard S⁵ ; Mohammadi M⁶ ; Abam F²
Source: Anti-Cancer Drugs Published:2022

Abstract

Today, nanoscience has grown and developed in various fields of medicine and treatment, including cancer treatment. Currently, the existing treatments, including chemotherapy and radiotherapy, cause side effects that are unpleasant to the patient. Due to the fact that anticancer drugs cause severe and widespread side effects, liposomes are considered as new drug carriers to minimize the untimely destruction of the drug when it is delivered to the target tissue and to prevent the side effects of toxic drugs. This systematic review study examined the importance of using liposomes as new drug carriers for the delivery of genes and anticancer drugs. The articles published in English in the databases of Google scholar, WoS, PubMed, Embase, Scopus and science direct were reviewed. According to the results of this study, a new targeted nanosystem has been used for loading and delivering anticancer drugs, genes and controlled drug release which has a significant therapeutic effect compared to the same amount of free drug. In general, liposomal systems have been considered because of their capability in preserving the effect of the drug along with reducing the side effects and toxicity of the drug, especially in the case of anticancer drugs. Accumulation of the drug in a target tissue which results in a reduction of the drug entry into other tissues is the main reason for reducing the side effects of these drugs. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.